Efficacy and Safety of Combined With Immunotherapy After Induction Therapy With Chemotherapy and Targeted Therapy in the First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer
The goal of this clinical trial is to explore the feasibility of a new mode of chemotherapy and bevacizumab induction therapy combined with immunotherapy as first-line treatment for patients with initially unresectable metastatic colorectal cancer (MSS). The main questions it aims to answer are:

1. To explore the efficacy and safety of this treatment mode
2. Try to study treatment benefit the characteristics of the crowd Participants will combined with immunotherapy after chemotherapy and bevacizumab induction therapy.
Colorectal Cancer
DRUG: Camrelizumab
PFS（Disease-free Survival）, Disease-free Survival, 11.5 months
ORR（Objective Remission Rate）, Objective Remission Rate, 2 years|Conversion resection rate, Conversion resection rate, 2 years|OS（Overall Survival）, Overall Survival, more than 2 years|Incidence of Treatment-Emergent Adverse Events, Treatment-Emergent Adverse Events，such as bleeding，thrombocytopenia，abnormal liver function，proteinuria，hypertension and so on, 2 years|DCR（Disease control rate）, Disease control rate, 2 years
The goal of this clinical trial is to explore the feasibility of a new mode of chemotherapy and bevacizumab induction therapy combined with immunotherapy as first-line treatment for patients with initially unresectable metastatic colorectal cancer (MSS). The main questions it aims to answer are:

1. To explore the efficacy and safety of this treatment mode
2. Try to study treatment benefit the characteristics of the crowd Participants will combined with immunotherapy after chemotherapy and bevacizumab induction therapy.